Movement Alert｜SKB BIO Rises 3.15% in Regular Trading, Dual-Payload ADC Drug SKB565 Approved for Clinical Trials Ahead of Interim Results Review

Market Focus

Aug 07

On August 7, SKB BIO rose 3.15% in regular trading, trading at 524.5 HKD/share, with turnover of approximately 74.77 million HKD.

On the news front, the company recently announced that its novel dual-payload ADC drug SKB565 received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors. SKB565 is the company's first dual-payload antibody-drug conjugate to enter the clinical stage, marking a critical step in its integrated \"ADC+IO\" development strategy.

Meanwhile, the company's board is scheduled to convene on August 17 to review interim results for the six months ending June 30, fueling market expectations for earnings delivery. Goldman Sachs and JP Morgan previously raised their target prices to 582.95 HKD and 648 HKD respectively, both maintaining buy ratings. Multiple catalysts converging near the mid-year results window have driven heightened investor attention.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1105886813"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105886813\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105886813?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 10:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105886813","market":"hk","top_or_hot":-1,"title":"Movement Alert｜SKB BIO Rises 3.15% in Regular Trading, Dual-Payload ADC Drug SKB565 Approved for Clinical Trials Ahead of Interim Results Review","media":"Market Focus","content":"<p><p>On August 7, SKB BIO rose 3.15% in regular trading, trading at 524.5 HKD/share, with turnover of approximately 74.77 million HKD.</p><p>On the news front, the company recently announced that its novel dual-payload ADC drug SKB565 received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors. SKB565 is the company's first dual-payload antibody-drug conjugate to enter the clinical stage, marking a critical step in its integrated \\\"ADC+IO\\\" development strategy.</p><p>Meanwhile, the company's board is scheduled to convene on August 17 to review interim results for the six months ending June 30, fueling market expectations for earnings delivery. Goldman Sachs and JP Morgan previously raised their target prices to 582.95 HKD and 648 HKD respectively, both maintaining buy ratings. Multiple catalysts converging near the mid-year results window have driven heightened investor attention.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜SKB BIO Rises 3.15% in Regular Trading, Dual-Payload ADC Drug SKB565 Approved for Clinical Trials Ahead of Interim Results Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜SKB BIO Rises 3.15% in Regular Trading, Dual-Payload ADC Drug SKB565 Approved for Clinical Trials Ahead of Interim Results Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 10:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, SKB BIO rose 3.15% in regular trading, trading at 524.5 HKD/share, with turnover of approximately 74.77 million HKD.</p><p>On the news front, the company recently announced that its novel dual-payload ADC drug SKB565 received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors. SKB565 is the company's first dual-payload antibody-drug conjugate to enter the clinical stage, marking a critical step in its integrated \\\"ADC+IO\\\" development strategy.</p><p>Meanwhile, the company's board is scheduled to convene on August 17 to review interim results for the six months ending June 30, fueling market expectations for earnings delivery. Goldman Sachs and JP Morgan previously raised their target prices to 582.95 HKD and 648 HKD respectively, both maintaining buy ratings. Multiple catalysts converging near the mid-year results window have driven heightened investor attention.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1105886813","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105886813","pubTimestamp":1786069036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, SKB BIO rose 3.15% in regular trading, trading at 524.5 HKD/share, with turnover of approximately 74.77 million HKD.On the news front, the company recently announced that its novel...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"走势提醒|SKB生物常规交易涨3.15%，双有效载荷ADC药物SKB565中期业绩审核前获批临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"On August 7, SKB BIO rose 3.15% in regular trading, trading at 524.5 HKD/share, with turnover of approximately 74.77 million HKD.On the news front, the company recently announced that its novel dual-payload ADC drug SKB565 received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors. SKB565 is the company's first dual-payload antibody-drug conjugate to enter the clinical stage, marking a critical step in its integrated \\\"ADC+IO\\\" development strategy.Meanwhile, the company's board is scheduled to convene on August 17 to review interim results for the six months ending June 30, fueling market expectations for earnings delivery. Goldman Sachs and JP Morgan previously raised their target prices to 582.95 HKD and 648 HKD respectively, both maintaining buy ratings. Multiple catalysts converging near the mid-year results window have driven heightened investor attention.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}